Switch theme
Sign up to access all valuation multiples
Oxford Nanopore Technologies PLC makes a novel generation of DNA/RNA sequencing technology that provides rich data and is fast, accessible, and easy to use. The company is predominantly involved in researching, developing, manufacturing, and commercializing a nanopore-based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). This enables its customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. The company's reportable segments are; Life Science Research Tools which generates key revenue, and COVID Testing.
2005
1.3K+
LTM Revenue $263M
LTM EBITDA -$144M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Oxford Nanopore Techs has a last 12-month revenue (LTM) of $263M and a last 12-month EBITDA of -$144M.
In the most recent fiscal year, Oxford Nanopore Techs achieved revenue of $246M and an EBITDA of -$125M.
Oxford Nanopore Techs expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Oxford Nanopore Techs valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $263M | XXX | $246M | XXX | XXX | XXX |
| Gross Profit | $151M | XXX | $142M | XXX | XXX | XXX |
| Gross Margin | 57% | XXX | 58% | XXX | XXX | XXX |
| EBITDA | -$144M | XXX | -$125M | XXX | XXX | XXX |
| EBITDA Margin | -55% | XXX | -51% | XXX | XXX | XXX |
| EBIT | -$207M | XXX | -$205M | XXX | XXX | XXX |
| EBIT Margin | -79% | XXX | -83% | XXX | XXX | XXX |
| Net Profit | -$195M | XXX | -$196M | XXX | XXX | XXX |
| Net Margin | -74% | XXX | -80% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Oxford Nanopore Techs's stock price is GBP 1 (or $2).
Oxford Nanopore Techs has current market cap of GBP 1.2B (or $1.6B), and EV of GBP 892M (or $1.2B).
See Oxford Nanopore Techs trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $1.6B | XXX | XXX | XXX | XXX | $-0.21 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Oxford Nanopore Techs has market cap of $1.6B and EV of $1.2B.
Oxford Nanopore Techs's trades at 4.9x EV/Revenue multiple, and -9.6x EV/EBITDA.
Equity research analysts estimate Oxford Nanopore Techs's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oxford Nanopore Techs has a P/E ratio of -8.2x.
See valuation multiples for Oxford Nanopore Techs and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| EV (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV/Revenue | 4.6x | XXX | 4.9x | XXX | XXX | XXX |
| EV/EBITDA | -8.3x | XXX | -9.6x | XXX | XXX | XXX |
| EV/EBIT | -5.8x | XXX | -5.9x | XXX | XXX | XXX |
| EV/Gross Profit | 7.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -8.2x | XXX | -8.1x | XXX | XXX | XXX |
| EV/FCF | -7.0x | XXX | -5.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOxford Nanopore Techs's last 12 month revenue growth is 25%
Oxford Nanopore Techs's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.
Oxford Nanopore Techs's rule of 40 is -38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Oxford Nanopore Techs's rule of X is 7% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Oxford Nanopore Techs and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 25% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Margin | -55% | XXX | -51% | XXX | XXX | XXX |
| EBITDA Growth | -22% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -38% | XXX | -26% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 7% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 54% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 141% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Zomedica | XXX | XXX | XXX | XXX | XXX | XXX |
| AnteoTech | XXX | XXX | XXX | XXX | XXX | XXX |
| Proteomics International | XXX | XXX | XXX | XXX | XXX | XXX |
| Biohit | XXX | XXX | XXX | XXX | XXX | XXX |
| Genomictree | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oxford Nanopore Techs acquired XXX companies to date.
Last acquisition by Oxford Nanopore Techs was XXXXXXXX, XXXXX XXXXX XXXXXX . Oxford Nanopore Techs acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Oxford Nanopore Techs founded? | Oxford Nanopore Techs was founded in 2005. |
| Where is Oxford Nanopore Techs headquartered? | Oxford Nanopore Techs is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Oxford Nanopore Techs have? | As of today, Oxford Nanopore Techs has 1.3K+ employees. |
| Who is the CEO of Oxford Nanopore Techs? | Oxford Nanopore Techs's CEO is Dr. Gurdial Sanghera. |
| Is Oxford Nanopore Techs publicy listed? | Yes, Oxford Nanopore Techs is a public company listed on LON. |
| What is the stock symbol of Oxford Nanopore Techs? | Oxford Nanopore Techs trades under ONT ticker. |
| When did Oxford Nanopore Techs go public? | Oxford Nanopore Techs went public in 2021. |
| Who are competitors of Oxford Nanopore Techs? | Similar companies to Oxford Nanopore Techs include e.g. Zomedica, AnteoTech, Proteomics International, Biohit. |
| What is the current market cap of Oxford Nanopore Techs? | Oxford Nanopore Techs's current market cap is $1.6B |
| What is the current revenue of Oxford Nanopore Techs? | Oxford Nanopore Techs's last 12 months revenue is $263M. |
| What is the current revenue growth of Oxford Nanopore Techs? | Oxford Nanopore Techs revenue growth (NTM/LTM) is 25%. |
| What is the current EV/Revenue multiple of Oxford Nanopore Techs? | Current revenue multiple of Oxford Nanopore Techs is 4.6x. |
| Is Oxford Nanopore Techs profitable? | Yes, Oxford Nanopore Techs is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Oxford Nanopore Techs? | Oxford Nanopore Techs's last 12 months EBITDA is -$144M. |
| What is Oxford Nanopore Techs's EBITDA margin? | Oxford Nanopore Techs's last 12 months EBITDA margin is -55%. |
| What is the current EV/EBITDA multiple of Oxford Nanopore Techs? | Current EBITDA multiple of Oxford Nanopore Techs is -8.3x. |
| What is the current FCF of Oxford Nanopore Techs? | Oxford Nanopore Techs's last 12 months FCF is -$171M. |
| What is Oxford Nanopore Techs's FCF margin? | Oxford Nanopore Techs's last 12 months FCF margin is -65%. |
| What is the current EV/FCF multiple of Oxford Nanopore Techs? | Current FCF multiple of Oxford Nanopore Techs is -7.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
